Profil des protéines inflammatoires régulées positivement dans les sérums de patients atteints de myasthénie grave.

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4743
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 10 Firefox
Genre :
Zodiaque : Lion
Âge : 61
Contact :
France

Profil des protéines inflammatoires régulées positivement dans les sérums de patients atteints de myasthénie grave.

Message par Pboulanger » 09 janv. 2017 10:54

:hi:

Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28045063
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image
Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients.
Molin CJ1, Westerberg E1, Punga AR1.
Sci Rep. 2017 Jan 3;7:39716. doi: 10.1038/srep39716.


This study describes specific patterns of elevated inflammatory proteins in clinical subtypes of myasthenia gravis (MG) patients. MG is a chronic, autoimmune neuromuscular disease with antibodies most commonly targeting the acetylcholine receptors (AChRab), which causes fluctuating skeletal muscle fatigue.
MG pathophysiology includes a strong component of inflammation, and a large proportion of patients with early onset MG additionally present thymus hyperplasia.
Due to the fluctuating nature and heterogeneity of the disease, there is a great need for objective biomarkers as well as novel potential inflammatory targets.
We examined the sera of 45 MG patients (40 AChRab seropositive and 5 AChRab seronegative), investigating 92 proteins associated with inflammation.
Eleven of the analysed proteins were significantly elevated compared to healthy controls, out of which the three most significant were:
matrix metalloproteinase 10 (MMP-10; p = 0.0004), transforming growth factor alpha (TGF-α; p = 0.0017) and extracellular newly identified receptor for advanced glycation end-products binding protein (EN-RAGE) (also known as protein S100-A12; p = 0.0054). Further, levels of MMP-10, C-X-C motif ligand 1 (CXCL1) and brain derived neurotrophic factor (BDNF) differed between early and late onset MG.
These novel targets provide valuable additional insight into the systemic inflammatory response in MG.
Amicalement,
Image

Répondre

Retourner vers « Informations »